Top news of the week: 18.08.2020.
Health care, Biotechnology, Clinical trial, Adverse event, Clinical research, Vaccine
Healthcare
100,000 volunteers have now signed up to the #COVID19 vaccines register 💉
But we still need more volunteers to help speed up efforts to find an effective vaccine.
More info:
▶️ https://t.co/szje8vfvK2
Register to participate in the vaccine clinical trials 👇🏼
OpenPublic encouraged to register for COVID-19 vaccine trials as 100,000 already sign-up
Over 100,000 people have volunteered to take part in COVID-19 vaccine trials, helping to speed up efforts to discover a safe and effective vaccine.
Developing new medicines isn't a job that can be done completely from home.
Here's how @skathire figured out testing for his employees - and now 50 other biotechs - with an avg turnaround time for results of 12 hrs.
Feat @gabriel_stacey @carolinesavello
https://t.co/gV9EKseqfA
OpenHow a biotech CEO figured out Covid-19 surveillance testing for 50 companies with 12-hour turnaround times
As testing turnaround times stretch to a week or more for some parts of the country, a group of 50 biotech companies has figured out a surveillance system with results in 12 hours.
RT @EBDgroup: “For us, there is no one-size-fits-all structure for our collaborations. Instead, we tailor our deals to what each individual partner needs,” says Dr. Dan Wang, Head,
@JNJInnovation, Asia Pacific. Read more in this exclusive interview >> https://t.co/ysTTUgd53O
OpenInterview – J&J’s multi-pronged approach to life science innovation, partnerships, and advanced technologies
Dr. Dan Wang, Head, Johnson & Johnson Innovation, Asia Pacific, and Dr. Sharon Chan, Head of JLABS @ Shanghai discuss its support of startups, interests in diverse disease areas, the ...
Regulatory Setback For Fennec Pharma, Ligand To Buy Pfenex, Inovio Says Phase 2/3 Coronavirus Vaccine Study Starts In September #BioTech via https://t.co/2sI0UxJbpn https://t.co/450hCzgIfZ
OpenThe Daily Biotech Pulse: Regulatory Setback For Fennec Pharma, Ligand To Buy Pfenex, Inovio Says Phase 2/3 Coronavirus Vaccine Study Starts In September
Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 10) Allovir Inc (NASDAQ: ALVR) BioLife Solutions Inc (NASDAQ: BLFS) BioSpecifics Technologies Corp. (NASDAQ: BSTC) (...
A great article in @Siftedeu today from @4BIO Capital Managing Partner @DmitryKuzmin on why we still won’t be prepared for the next pandemic https://t.co/xgNIt0ubZw
OpenWhy we still won’t be prepared for the next pandemic
We need a new funding model for drug discovery to support the small biotech startups which develop new drugs far more cost-effectively than big pharma.
Bharat Biotech-ICMR's Covaxin is safe, preliminary results suggest: Report #BioTech via https://t.co/2sI0UxJbpn https://t.co/1avX3gReKi
OpenCoronavirus vaccine update | Bharat Biotech-ICMR's Covaxin is safe, preliminary results suggest: Report
An investigator said, if the process continued smoothly, the vaccine would be available in the first half of 2021.
RT @emmadinortey: US Makes Deal with Biotech Company for 100 Million Doses of Potential COVID-19 Vaccine https://t.co/CKXDuzxZQc
OpenUS Makes Deal with Biotech Company for 100 Million Doses of Potential COVID-19 Vaccine
US%20Makes%20Deal%20with%20Biotech%20Company%20for%20100%20Million%20Doses%20of%20Potential%20COVID-19%20Vaccine
RT @SunilKapadia3: Bharat Biotech-ICMR developed Covaxin is safe, show preliminary phase I results https://t.co/Q8DVT7JjWR via @economictimes
OpenBharat Biotech-ICMR developed Covaxin is safe, show preliminary phase I results
“The vaccine is safe. We have not observed any adverse events in any of the volunteers at our site,” said Savita Verma, principal investigator, who is leading the trial.